October 04, 2024

Omalizumab Boosts Tolerance to Food Allergens: Study

In a phase 3 trial, 67% of children treated with omalizumab tolerated 600 mg of peanut protein, a dramatic increase over just 7% with placebo, highlighting omalizumab’s potential in managing pediatric food allergies.

Conexiant

October 04, 2024

Regulator Reviews Hair-Loss Drugs Over Suicide Risk

European drugs regulator is reviewing anti hair-loss drugs for potential risk of psychiatric side effects, including suicidal thoughts and behavior.

Reuters

October 03, 2024

Experts Urged Caution on Mouth Taping Trend

Social media fuels mouth taping trend with 7 million TikTok views, prompting medical experts to scrutinize limited data on forced mouth closure during sleep.

Conexiant

October 03, 2024

Topical Vitamin D with Standard Acne Therapy Reduces Inflammation

A recent study found that topical vitamin D was associated with a reduction in proinflammatory cytokine levels and the severity of inflammatory acne lesions. Additional studies are needed to gain a clearer understanding of its mechanism of action.

Conexiant

October 02, 2024

BP180 Antibodies Track Severity in Bullous Pemphigoid

A systematic review of 14 studies found that anti-BP180 autoantibody levels strongly correlate with bullous pemphigoid severity, potentially offering clinicians a valuable biomarker for disease monitoring and treatment guidance.

Conexiant

September 30, 2024

Thyroid Cancer Radioactive Iodine Tied to Melanoma Risk

New study reveals higher risk of melanoma and nonkeratinocyte skin cancers for thyroid cancer patients treated with radioactive iodine therapy, with particular concern for head and neck region.

Conexiant

September 30, 2024

Roflumilast Cream Effective for Atopic Dermatitis in Phase III Trials

Two phase III clinical trials reveal promising results of once-daily roflumilast cream, 0.15%, in improving symptoms of atopic dermatitis within 4 weeks.

Conexiant

September 27, 2024

Over 3,600 Food Contact Chemicals Found in Humans

Eighty FCCs had properties that warrant further investigation for potential health concerns, such as carcinogenic, mutagenic, and reproductive toxicity.

Conexiant

September 25, 2024

Home vs. Office: Psoriasis Treatment Showdown

Home-based narrowband UV-B phototherapy for psoriasis achieved superior treatment adherence, with 51.4% of patients receiving at least 24 treatments compared to only 15.9% in the office-based group.

Conexiant